Amesite Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Amesite Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $110.5K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $166.9K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $845.0K | Jan 2, 2025 |
| FY2023 | Jun 30, 2022 | $697.0K | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | $674.6K | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | $59.7K | Sep 10, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($3.62M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($4.40M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($4.15M) | Jan 2, 2025 |
| FY2023 | Jun 30, 2022 | ($9.06M) | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | ($11.59M) | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | ($4.17M) | Sep 10, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($3.60M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($4.58M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($4.22M) | Jan 2, 2025 |
| FY2023 | Jun 30, 2022 | ($9.06M) | Oct 6, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $691.2K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $1.07M | Sep 29, 2025 |
| FY2023 | Jun 30, 2023 | $1.52M | Oct 6, 2023 |
| FY2023 | Jun 30, 2022 | $3.06M | Oct 6, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($2.46M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($2.81M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($3.25M) | Jan 2, 2025 |
| FY2023 | Jun 30, 2022 | ($6.72M) | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | ($5.33M) | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | ($2.81M) | Sep 10, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2024 | $1.2K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $27.1K | Jan 2, 2025 |
| FY2023 | Jun 30, 2022 | $16.6K | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | $73.4K | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | $10.8K | Sep 10, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.10M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $3.31M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $6.35M | Jan 2, 2025 |
| FY2023 | Jun 30, 2022 | $8.88M | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | $12.48M | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | $5.70M | Sep 10, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $2.74M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $2.52M | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | $6.08M | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | $8.14M | Jan 2, 2025 |
| FY2023 | Jun 30, 2021 | $11.74M | Oct 6, 2023 |
| FY2022 | Jun 30, 2020 | $3.00M | Sep 28, 2022 |
| FY2021 | Jun 30, 2019 | $1.84M | Sep 10, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($41.45M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($37.83M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($33.43M) | Jan 2, 2025 |
| FY2023 | Jun 30, 2022 | ($29.28M) | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | ($20.22M) | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | ($8.63M) | Sep 10, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $2.33M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $2.07M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $5.26M | Jan 2, 2025 |
| FY2021 | Jun 30, 2021 | $10.71M | Sep 10, 2021 |
| FY2021 | Jun 30, 2020 | $4.09M | Sep 10, 2021 |
| FY2021 | Jun 30, 2019 | $1.01M | Sep 10, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | (1) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | (1) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | (1) | Jan 2, 2025 |
| FY2023 | Jun 30, 2022 | (4) | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | 0 | Sep 10, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | (1) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | (1) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | (1) | Jan 2, 2025 |
| FY2023 | Jun 30, 2022 | (4) | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Sep 28, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 4.57M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 2.54M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 2.54M | Jan 2, 2025 |
| FY2023 | Jun 30, 2022 | 2.17M | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | 21.06M | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | 16.23M | Sep 10, 2021 |